Rosopatamab is a humanized anti-PSMA IgG1 monoclonal antibody used in cancer research, particularly for prostate cancer; it can be conjugated with the bifunctional chelator DOTA-NHS ester and the low-energy beta-emitting radioisotope lutetium-177 (177Lu) to form a radiolabeled immunoconjugate that effectively targets malignant prostate cells.